Carbetocin
Carbetocin is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target oxytocin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 4 | 2 | 8 | 18 | 33 | 64 |
| Postpartum hemorrhage | D006473 | — | O72 | 4 | 3 | 9 | 14 | 28 | 56 |
| Obstetric labor complications | D007744 | — | — | — | — | — | 1 | 7 | 8 |
| Cesarean section | D002585 | — | — | 1 | 1 | 1 | 2 | 1 | 5 |
| Uterine myomectomy | D063186 | — | — | — | — | — | 3 | 1 | 4 |
| Myoma | D009214 | — | D21 | — | — | — | 1 | 3 | 4 |
| Placenta previa | D010923 | EFO_0007442 | O44 | — | — | 2 | 1 | — | 3 |
| Uterine inertia | D014593 | EFO_1001863 | O62.2 | — | — | — | 2 | 1 | 3 |
| Leiomyoma | D007889 | HP_0000131 | D25 | 1 | — | — | 1 | — | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | 2 | — | 2 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | 1 | 3 | — | — | 4 |
| Syndrome | D013577 | — | — | — | 1 | 3 | — | — | 4 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 2 | — | 1 | 3 |
| Hyperphagia | D006963 | — | R63.2 | — | 1 | 2 | — | — | 3 |
| Eclampsia | D004461 | HP_0100601 | O15 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Maternal obesity | D000079262 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| High-risk pregnancy | D018566 | — | — | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Hyperalgesia | D006930 | — | — | — | — | — | — | 1 | 1 |
| Central nervous system sensitization | D059333 | — | — | — | — | — | — | 1 | 1 |
| Placenta accreta | D010921 | EFO_0007440 | O43.21 | — | — | — | — | 1 | 1 |
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
| Postoperative hemorrhage | D019106 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carbetocin |
| INN | carbetocin |
| Description | Carbetocin is oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. It has a role as an oxytocic. |
| Classification | Protein |
| Drug class | oxytocin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 37025-55-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301668 |
| ChEBI ID | 59204 |
| PubChem CID | 16681432 |
| DrugBank | DB01282 |
| UNII ID | 88TWF8015Y (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 771 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
115 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use